Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations.  He highlights arguably on the best theragnostic radionuclides, Tin-117m, it’s difference and benefits from other radioisotopes and details a study aimed to determine, tin-117m with its low-energy conversion electron emission, and thus a shorter range in tissue should cause less radiation damage to the bone. 

Biography:

Suresh C. Srivastava, Senior Medical Scientist Emeritus, Collider-Accelerator Department, BNL CAD, Brookhaven National Laboratory, Upton, New York, US Department of Energy